

SUPPLEMENTARY.

Table S2. Post hoc comparisons of the Symptoms Qualifier Scales positive, negative, and depressive symptom domain baseline scores between the three paliperidone groups

Symptoms	Dosage form	Symptoms	Dosage form	Mean Difference	SE	df	t	p	P _{tukey}	P _{bonferroni}
Positive symptoms										
Visit 1	OP	Visit 1	PP1M	-0.0435	0.2079	62.0	-0.2092	0.824	1.000	1.000
		Visit 1	PP3M	-0.1667	0.1994	62.0	-0.8360	0.373	1.000	1.000
Visit 1	PP1M	Visit 1	PP3M	-0.1232	0.1618	62.0	-0.7615	0.449	1.000	1.000
Negative symptoms										
Visit 1	OP	Visit 1	PP1M	0.4348	0.1756	62.0	2.4761	0.016	0.472	1.000
		Visit 1	PP3M	0.2333	0.1680	62.0	1.3888	0.170	0.985	1.000
Visit 1	PP1M	Visit 1	PP3M	0.1130	0.1346	62.0	0.8398	0.404	0.890	1.000
Depressive symptoms										
Visit 1	OP	Visit 1	PP1M	0.27778	0.2534	62.0	1.0962	0.277	0.999	1.000
		Visit 1	PP3M	0.51905	0.2443	62.0	2.1244	0.037	0.715	1.000
Visit 1	PP1M	Visit 1	PP3M	0.24127	0.1871	62.0	1.2896	0.201	0.993	1.000

Note: df — the degrees of freedom; p — the significance level (p-value); OP — oral paliperidone; PP1M — paliperidone palmitate once a month; PP3M — paliperidone palmitate once every three months.